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The molecular mechanisms of drug resistance in 19 strains of Vibrio fluvialis isolated from 1998 to 2002 in
Kolkata, India, were investigated. Class 1 integrons were detected in eight strains, and four strains were found
to carry SXT integrases. In the presence of carbonyl cyanide m-chlorophenylhydrazone or reserpine, all
nalidixic acid- and ciprofloxacin-resistant strains became sensitive, suggesting that drug efflux plays a major
role in quinolone resistance in V. fluvialis. It was further seen that strains which had MICs of >25 g/ml for
nalidixic acid had a sense mutation (Ser to Ile) at position 83 of the quinolone resistance-determining region
of gyrA. All except one of the integron- and SXT integrase-bearing strains belonged to the same ribotype.
Vibrio fluvialis, a halophilic Vibrio species, has been associ-
ated with sporadic outbreaks of diarrhea worldwide (10, 11,
13), which is clinically very similar to cholera. It is being iso-
lated with an increased frequency from hospitalized patients in
Kolkata, India, with cholera-like illnesses (our unpublished
observations). The V. fluvialis strains isolated in the past were
found to be resistant to several antibiotics (13). However, there
is a paucity of information on the genetic basis of drug resis-
tance in these strains. Antibiotic resistance arises through mul-
tiple means and can be mediated by plasmids, integrons, and
transposons, besides mutations in target genes and the over-
expression of efflux systems (4, 5, 6, 8). Only two reports (1, 2)
have addressed this issue. In those studies, the presence of the
drug cassettes aac(3)-Id and aadA7, which confer resistance to
gentamicin, streptomycin, and spectinomycin, were identified
in V. fluvialis, as was an SXT constin (6). In this study, we
performed antibiotic susceptibility tests with 19 strains of V.
fluvialis isolated from hospitalized patients in Kolkata, India,
recovered from 1998 to 2002 and also analyzed their drug
resistance profiles.
MATERIALS AND METHODS
V. fluvialis strains were isolated from patients with acute cholera-like di-
arrhea admitted to the Infectious Diseases Hospital, Kolkata, India, between
1998 and 2002.
Bacteriology. V. fluvialis isolates were identified by using the API 20E system
(bioMerieux, Marcy l’Etoile, France) and also by 16S rRNA gene sequencing.
Antimicrobial susceptibility testing andMIC determination. The isolates were
examined for antibiotic resistance as described previously (17). The MICs of
ciprofloxacin and nalidixic acid were determined as described in the CLSI stan-
dards (7).
Bacterial genomic DNA and plasmid isolation. Genomic and plasmid DNA
was extracted from the isolates by a method described earlier (17), except that
for plasmid isolation, 0.75 ml of culture and twice the suggested volumes of all
three solutions were used.
Bacterial transformation and plating on selective media. Escherichia coli
JM109 electrocompetent cells, prepared according to the manufacturer’s recom-
mendations (Bio-Rad Laboratories, Richmond, Calif.), were transformed with
30 ng of plasmid preparations and selected as described before (17).
Ribotyping. The rRNA gene restriction patterns (ribotypes) of the test strains
were determined exactly as described before (16).
PCR amplifications, sequence analyses, and GenBank accession numbers.
PCRs for determination of the presence of class 1 integrons, SXT integrases, and
mutations in the quinolone resistance-determining region (QRDRs) of the gyrA,
gyrB, parC, and parE genes of quinolone-resistant strains were carried out with
the appropriate primers (Table 1). Elution of the amplicons was done as de-
scribed previously. Sequencing was carried out by following the manufacturer’s
instructions (BigDye Terminator kit; Applied Biosystems) with an ABI Prism 310
instrument. The identities of the sequences were established through a database
search by using the BLAST program (3), and mutations were identified by
comparison of the sequences with the V. cholerae genome sequence (9). Se-
quences with the following accession numbers were obtained from GenBank:
AY605692, strain BD146 (dfrA15); AY605688, strain BD73 (dfrA1); AY605684,
strain BD123 (aadA7); AY605683, strain BD51 [aac(3)-Id and aadA7]; and
AY103456, strain PL78/6 (dfrA1).
Accumulation studies with quinolones. The accumulation of quinolones was
examined by the method of Mortimer and Piddock (15), with minor modifica-
tions: phosphate-buffered saline (0.136 M NaCl, 0.0026 M KCl, 0.01 M
Na2HPO4, 0.00176 M KH2PO4; pH 7.0) was used instead of sodium phosphate
buffer, and cell lysis was carried out for 6 h. Carbonyl cyanide m-chlorophenyl-
hydrazone (CCCP) or reserpine was added to a final concentration of 20 g/ml.
The fluorescence of the supernatant was measured with a spectrofluorimeter
(Tegimenta AG type SFM 25).
RESULTS
Drug resistance in V. fluvialis. The V. fluvialis strains were
found to be resistant to one or more antibiotics, with 75% of
the strains being resistant to ampicillin, furazolidone, nalidixic
acid, and streptomycin (Table 2).
Class 1 integrons and mapping of resistance gene cassettes.
Eight of the 19 strains produced a 0.8-kb amplicon with the
primers qacE1-F and Sul1B (Table 1; Fig. 1). A 0.3-kb am-
plicon was obtained with the L2 and L3 primer pair (Table 1;
Fig. 1). Sequencing of the 0.8-kb and 0.3-kb amplicons fol-
lowed by BLAST analysis revealed 100% sequence identity of
these amplicons with the 3 conserved sequence (3 CS) and 5
CS, respectively, of class 1 integrons (8, 12). PCR carried out
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with primers in-F (5 CS) and in-B (3 CS) (Table 1; Fig. 1)
produced amplicons of four distinct size classes: 0.7, 1.0, 1.25,
and 1.5 kb. Sequence analysis of the 0.7-kb amplicon revealed
the presence of the dfrA15 gene cassette in strain BD146 (Ta-
ble 2; Fig. 1). The 1.25-kb amplicon, generated by strains
PL78/6 and BD73, harbored the dfrA1 gene cassette and the
gene cassette of an unknown gene (orfC) (Table 2; Fig. 1). The
aadA7 gene cassette was found on the 1.0-kb PCR product
obtained with BD123 (Table 2; Fig. 1). The 1.5-kb amplicon
from strain BD51 harbored two cassettes, aac(3)-Id and aadA7
TABLE 1. Primers used in this study
Primer Sequence GenBankaccession no. Position
Size of
amplicon (kb) Reference
gyrA-F AATGTGCTGGGCAACGACTGG AE003852 157–177 0.25 5
gyrA-R GTGCGCGATTTTCGACATACG AE003852 376–396 0.25 5
gyrB-F GGAAATGACTCGCCGTAAAGG AE003852 1170–1190 0.3 5
gyrB-R GTTGTGATAACGCAGTTTATCTGGG AE003852 1455–1479 0.3 5
parC-F GTCTGAGTTGGGTCTCTCGGC AE003852 162–188 0.3 5
parC-R AGAATCTCGGCAAACTTTGACAG AE003852 388–411 0.3 5
parE-F ATGCGTGCCAGCAAGAAAGTG AE003852 1138–1161 0.3 5
parE-R TTATCGCTGTCAGGGTCAATCC AE003852 1408–1428 0.3 5
in-F GGC ATC CAA GCA GCA AGC U12338 1416–1433 Variable 8
in-B AAG CAG ACT TGA CCT GAT U12338 4831–4814 Variable 8
qacE1-F ATCGCAATAGTTGGCGAAGT X15370 211–230 0.8 8
Sul1-B GCAAGGCGGAAACCCGCC X12869 1360–1341 0.8 8
L2 GACGATGCGTGGAGACC M73819 910–926 0.3 14
L3 CTTGCTGCTTGGAtGCC M73819 1206–1190 0.3 14
SXT-F TTATCGTTTCGATGGC AF099172 129–144 0.8 17
SXT-B GCTCTTCTTGTCCGTTC AF099172 915–931 0.8 17
TABLE 2. Phenotypic and genotypic characterization of V. fluvialis strains
Strain
name Antibiogram
a Yr of
isolation
Presence
of class I
integrons
Size of
amplicon
(kb)
Gene cassette Presenceof SXT
Plasmid
size (kb)
gyrAb
mutation
MIC
(g/ml) Efflux pump
NAL CIP
PMF
for
NAL
ABC
for
NAL
PMF
for
CIP
ABC
for
CIP
PL78/6 AMP, CHL, GEN, NAL,
NEO, SM, STR, SZ,
TET, TMP
1998  1.25 dfrA1 orfC  240 Ser-Iso 100 0.5    
PL45 AMP, FUR, SM, STR, SX,
SZ, TMP
1998   2–8 0.5 0.5    
PL78/7b AMP, GEN, NAL, NEO,
SM, STR, SX, SZ, TMP
1998  Null  2–8 Ser-Iso 100 0.5    
PG39 AMP, FUR, NEO 1998   0.5 0.5    
PG41 AMP 1998   0.5 0.5    
PG152 AMP, FUR, NEO 1998   0.5 0.5    
PL169b AMP, FUR, NEO 1998   0.5 0.5    
PL171b AMP, CHL, CIP, FUR,
NAL, NEO, SM, STR,
SX, SZ, TET
1998  Null  Ser-Iso 100 10    
CRC159 AMP, FUR, NAL, NEO 2000   10 0.5    
CRC233 AMP, FUR, GEN, NAL,
NEO, STR, SX, SZ,
TET
2000  Null  Ser-Iso 25 0.5    
CRC111 AMP, FUR, NAL, SM, SZ 2000   6 10 0.5    
BD51 AMP, CHL, FUR, GEN,
NAL, STR
2002  1.5 aac(3)-Id aadA7  2–8 Ser-Iso 100 0.5    
BD73 AMP, CHL, FUR, NAL,
STR
2002  1.25 dfrA1 orfC  15 0.5    
BD123 AMP, CHL, FUR, GEN,
NAL, STR
2002  1.0 AadA7  2–8 Ser-Iso 100 0.5    
BD146 AMP, CHL, CIP, GEN,
NAL, STR
2002  0.7 dfrA15  2–8 Ser-Iso 100 10    
BD36 AMP, FUR, GEN, NAL,
STR
2002   2–8 10 0.5    
BD56 AMP, FUR, NAL, STR 2002   2–8 10 0.5    
BD135 CHL, NAL, STR 2002   2–8 Ser-Iso 100 0.5    
BD159 AMP, FUR, GEN, NAL,
STR
2002   2–8 Ser-Iso 100 0.5    
a Abbreviations: AMP, ampicillin (10 g); CHL, chloramphenicol (30 g); FUR, furazolidone (50 g); GEN, gentamicin (10 g); STR, streptomycin (10 g); TET,
tetracycline (30 g); NEO, neomycin (30 g); SM, sulfamethizole (300 g); SZ, sulfamethoxazole (50 g); SX, sulfadiazine (100 g); and TMP, trimethoprim (25 g);
NAL, nalidixic acid; CIP, ciprofloxacin. Interpretation of the results was done by using the criteria recommended by the CLSI (7), except that no distinction was made
between intermediate and full resistance. Escherichia coli ATCC 25922 was used for quality control.
b gyrA mutations were identified by comparing the sequences obtained with the corresponding sequences of V. cholerae (9).
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(Table 2; Fig. 1). In strains PL78/7b, PL171b, and CRC233, no
amplicon could be generated with primer pair in-F and in-B
(Table 1; Fig. 1). However, a 1.2-kb amplicon was obtained
with primers L2 and Sul1B. Sequencing of this amplicon re-
vealed the presence of a “null” cassette (17) in this class 1
integron.
Occurrence of SXT integrase gene. To look for SXT, prim-
ers SXT-F and SXT-B, whose sequences are internal to that of
the SXT integrase gene (SXT int), were used (Table 1) for
amplification of the putative SXT int. A 0.8-kb amplicon was
obtained with only four strains, namely, strains PL78/6, PL78/
7b, PL171b, and BD51, which, upon sequencing, exhibited
100% homology with the relevant portion of the SXT int gene
(17), suggesting the presence of SXT constins or parts thereof
in these strains.
Resistance to quinolones: analysis for QRDRs in target
genes. Fourteen of the 19 strains were resistant to the nonflu-
orinated quinolone nalidixic acid and two were additionally
resistant to ciprofloxacin. The nalidixic acid-resistant strains
could broadly be classified into two groups: one with MICs
between 10 and 20 g/ml and the other with MICs 25 g/ml
(Table 2). Quinolone resistance in bacteria is mainly linked to
the mutations in the QRDRs of the gyrAB and parCE genes.
To check for the mutations in QRDRs, primers gyrA-F and
gyrA-R and primers parC-F and parC-R (Table 1), respec-
tively, were used to amplify these regions. Sequencing of the
0.25-kb amplicon obtained with all strains for the gyrA QRDR
showed the presence of a mutation at position 83, which led to
the replacement of serine with isoleucine in nine strains, which
had MICs 25 g/ml for nalidixic acid. No mutation could be
detected in any of the amplicons, an amplicon of 0.25 kb for
parC and an amplicon of 0.3 kb for both the gyrB and the parE
QRDRs, with the appropriate primers (Table 1).
Involvement of efflux pumps. Although strains BD36, BD56,
BD73, CRC111, and CRC159 were resistant to 10 to 15 g/ml
of nalidixic acid, they did not have any mutations in the
QRDRs of target genes. This indicated that other mechanisms
could be responsible for this level of nalidixic acid resistance
observed in these strains. To examine if multidrug resistance
pumps are involved in conferring quinolone resistance to V.
fluvialis, the level of accumulation of quinolones in the absence
and the presence of the efflux pump inhibitors, namely, CCCP
(an inhibitor of the proton motive force [PMF]) and reserpine
(a plant alkaloid known to inhibit the ATP binding cassette
[ABC transporters]), was measured. It was seen that irrespec-
tive of the MICs, both CCCP and reserpine could prevent the
accumulation of nalidixic acid in all nalidixic acid-resistant
strains (Fig. 2). These same two inhibitors could also prevent
the accumulation of ciprofloxacin in two strains, strains
PL171b and BD146, which were additionally resistant to this
drug. The results (Fig. 3) indicated that efflux pumps indeed
had a role here also.
Plasmid carriage and resistance conferred by plasmids.
Eleven of the 19 strains had plasmids, of which 10 had plasmids
ranging in size from 2 to 8 kb. Strain PL78/6 had a 240-kb
plasmid (Table 2). All plasmids in the 2- to 8-kb range, except
the ones from strain CRC111, could transform E. coli JM109
to ampicillin resistance (data not shown). No transformant
could be obtained with the 6-kb plasmid from CRC111. The
240-kb plasmid from PL78/6 could transfer resistance to strep-
tomycin, sulfamethoxazole, and ampicillin (data not shown).
DISCUSSION
The study described in this paper was undertaken to un-
ravel the molecular basis of drug resistance in V. fluvialis
strains isolated in Kolkata, India. Compared to only 37% of
the isolates recovered in 1998, 100% of the isolates recov-
ered in 2002 were resistant to quinolones. Eight strains were
found to carry class 1 integrons. Although an integron in a
V. fluvialis strain was detected for the first time in 2002 (1),
our work revealed that integrons have actually been present
in V. fluvialis at least since 1998. Although the “linked” gene
cassettes aadA7 and aac(3)-Id were detected in V. fluvialis
FIG. 1. Diagrammatic representation of the different types of gene cassettes identified in the class 1 integrons in V. fluvialis strains. Solid lines,
gene cassettes; solid circles, 59-base elements; hatched box, attI recombination site. The locations of the 5 CSs and the 3 CSs of class 1 integrons
and those of the primer pair qacEI-F and Sul1B and primer pair in-F (5 CS) and in-B (3 CS) are shown at the bottom.
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earlier (1), the aadA7 gene cassette detected in BD123 (Ta-
ble 2 and Fig. 1), which occurs singly, has not been found in
any Vibrio strain so far. Our studies further showed that
although all the strains were drug resistant, only five har-
bored integrons with drug cassettes which accounted for
resistance to only a few antibiotics (Table 2). Although
almost all of the strains were resistant to trimethoprim, only
three strains, strains PL78/6, BD73, and BD146, had dfrA1
and dfrA15 genes, which confer resistance to this drug.
Quite surprisingly, with the exception of four strains, SXT
integrases could not be detected in any other strain (Table
2). We found that 11 strains harbored plasmids, but except
in 2 strains, they carried genes only for ampicillin resistance.
It was of interest that except for strain CRC233, all inte-
gron- and SXT int-bearing strains belonged to a single ri-
botype (data not shown). Quinolone resistance in these
strains could be traced either to mutations in the QRDRs of
gyrA or to the presence of efflux pumps, or both. Efflux
pumps alone were responsible for the nalidixic acid resis-
tance phenotype in the strains with MICs between 10 and 15
g/ml, whereas both mutations in the gyrA QRDR and efflux
pumps were responsible for nalidixic acid resistance in
strains with MICs 25 g/ml.
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